

Supplementary Table 8. Quality of the evidence assessment for included studies evaluating the effects of IF in adults with overweight/obesity

No. of studies	Design	Quality assessment				No. of patients			Effect		
		Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	IF	Control	Relative (95% CI)	Absolute	Quality
HbA1c (follow-up 12–24 wk; better indicated by lower values)											
3	Randomized trials	Serious	No serious inconsistency	Serious	Serious	None	88	85	-	MD, 0.11 higher (0.04 lower–0.26 higher)	Very low
Fasting glucose, mg/dL (follow-up 12–24 wk; better indicated by lower values)											
5	Randomized trials	No serious risk of bias	No serious inconsistency	Serious	Serious	None	179	180	-	MD, 0.89 lower (4.3 lower–2.53 higher)	Low
Fasting insulin, μU/mL (follow-up 12–24 wk; better indicated by lower values)											
4	Randomized trials	No serious risk of bias	No serious inconsistency	Serious	Serious	None	154	160	-	MD, 0.43 lower (1.99 lower–1.14 higher)	Low
BW, kg (follow-up 12–24 wk; better indicated by lower values)											
8	Randomized trials	Serious	No serious inconsistency	Serious	Serious	None	274	280	-	MD, 1.22 lower (3.49 lower–1.05 higher)	Very low
HOMA-IR (follow-up 12–24 wk; better indicated by lower values)											
2	Randomized trials	Serious	No serious inconsistency	Serious	Serious	None	57	62	-	MD, 0.22 lower (1.48 lower–1.05 higher)	Very low
BMI, kg/m² (follow-up 12–24 wk; better indicated by lower values)											
5	Randomized trials	No serious risk of bias	No serious inconsistency	Serious	Serious	None	192	188	-	MD, 0.49 lower (1.13 lower–0.14 higher)	Very low
BW, kg (follow-up 12–24 wk; better indicated by lower values)											
8	Randomized trials	No serious risk of bias	No serious inconsistency	Serious	Serious	None	274	280	-	MD, 1.22 lower (3.49 lower–1.05 higher)	Low
WC, cm (follow-up 12–24 wk; better indicated by lower values)											
3	Randomized trials	Serious	No serious inconsistency	Serious	Serious	None	93	87	-	MD, 1.95 lower (4.09 lower–0.2 higher)	Very low
SBP, mm Hg (follow-up 12–24 wk; better indicated by lower values)											
6	Randomized trials	No serious risk of bias	Serious	Serious	Serious	None	203	201	-	MD, 0.87 higher (2.56 lower–4.39 higher)	Very low
DBP, mm Hg (follow-up 12–24 wk; better indicated by lower values)											
6	Randomized trials	No serious risk of bias	Serious	Serious	Serious	None	203	201	-	MD, 0.16 lower (2.89 lower–2.56 higher)	Very low

(Continued to the next page)

Supplementary Table 8. Continued

No. of studies	Design	Risk of bias	Quality assessment				No. of patients		Effect	
			Indirectness	Imprecision	Other considerations	IF	Control	Relative (95% CI)	Absolute	Quality
Fat free mass, kg (follow-up 12–24 wk; better indicated by lower values)										
8	Randomized trials	Serious	No serious inconsistency	Serious	Serious	None	269	271	-	MD, 0.36 lower (0.87 lower–0.16 higher)
Fat mass, kg (follow-up 12–24 wk; better indicated by lower values)										
8	Randomized trials	Serious	No serious inconsistency	Serious	Serious	None	269	271	-	MD, 0.67 lower (1.95 lower–0.62 higher)
Fat mass, % (follow-up 12–24 wk; better indicated by lower values)										
3	Randomized trials	Serious	No serious inconsistency	Serious	Serious	None	73	69	-	MD, 0.27 higher (0.48 lower–1.01 higher)
HDL-C, mg/dL (follow-up 12–24 wk; better indicated by higher values)										
6	Randomized trials	Serious	No serious inconsistency	Serious	Serious	None	218	214	-	MD, 0.17 lower (3.27 lower–2.89 higher)
LDL-C, mg/dL (follow-up 12–24 wk; better indicated by lower values)										
5	Randomized trials	Serious	No serious inconsistency	Serious	Serious	None	193	194	-	MD, 0.24 lower (5.08 lower–4.59 higher)
TG, mg/dL (follow-up 12–24 wk; better indicated by lower values)										
6	Randomized trials	Serious	No serious inconsistency	Serious	Serious	None	218	214	-	MD, 1.51 lower (17.06 lower–14.04 higher)
HbA1c (Copy; follow-up 12–24 wk; better indicated by lower values)										
3	Randomized trials	Serious	No serious inconsistency	Serious	Serious	None	88	85	-	MD, 0.11 higher (0.04 lower–0.26 higher)
BW, kg (Copy; follow-up 12–24 wk; better indicated by lower values)										
8	Randomized trials	Serious	No serious inconsistency	Serious	Serious	None	274	280	-	MD, 1.22 lower (3.49 lower–1.05 higher)

IF, intermittent fasting; CI, confidence interval; HbA1c, glycosylated hemoglobin; MD, mean difference; BW, body weight; HOMA-IR, homeostatic model assessment for insulin resistance; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.